Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment

@article{Putko2014AndersonFabryCP,
  title={Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment},
  author={B. Putko and Kevin C Wen and R. Thompson and J. Mullen and M. Shanks and Haran Yogasundaram and C. Sergi and G. Oudit},
  journal={Heart Failure Reviews},
  year={2014},
  volume={20},
  pages={179-191}
}
  • B. Putko, Kevin C Wen, +5 authors G. Oudit
  • Published 2014
  • Medicine
  • Heart Failure Reviews
  • Anderson-Fabry disease (AFD) is a lysosomal storage disease caused by the inappropriate accumulation of globotriaosylceramide in tissues due to a deficiency in the enzyme α-galactosidase A (α-Gal A). Anderson-Fabry cardiomyopathy is characterized by structural, valvular, vascular and conduction abnormalities, and is now the most common cause of mortality in patients with AFD. Large-scale metabolic and genetic screening studies have revealed AFD to be prevalent in populations of diverse ethnic… CONTINUE READING
    36 Citations
    Diagnosis and Screening of Patients with Fabry Disease
    • Highly Influenced
    • PDF
    Anderson-Fabry disease in heart failure
    • 11
    • PDF
    [The neurological manifestations of Fabry disease. A review].
    • 2
    • PDF
    Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy
    • 1
    • PDF

    References

    SHOWING 1-10 OF 120 REFERENCES
    When should cardiologists suspect Anderson-Fabry disease?
    • 41
    Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.
    • 261
    • PDF
    Cardiac manifestations of Anderson-Fabry disease in heterozygous females.
    • 169
    • Highly Influential
    • PDF
    Enzyme replacement therapy for Fabry disease: some answers but more questions
    • 31
    • PDF
    Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement
    • 334
    • PDF
    Agalsidase-Beta Therapy for Advanced Fabry Disease
    • 491
    • PDF
    Cardiac manifestations in Fabry disease
    • 86
    Enzyme replacement therapy for Anderson-Fabry disease.
    • 100
    Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females
    • 575
    • PDF